Call our support: +31 20 8084 414
  • Log In
My Cart
Toggle Nav
Search
Advanced Search
Menu
Account

Rydapt (midostaurin)

€20,717.25
In stock
SKU
Rydapt (midostaurin)

How to buy Rydapt (midostaurin): You can order Rydapt (midostaurin) from TheSocialMedwork if the drug has not been approved or is not available in your country. 

Oncology Leukemia
Marketing Authorisation Holder Novartis Europharm Limited
Mode of Action Kinase inhibitor (chemotherapy)
Administration Oral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA
Strength 25 milligram
Package 112 Capsules
Loading...

What is Rydapt (midostaurin) for?

Rydapt (midostaurin) is indicated for the treatment of patients with1,3:

  • Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with chemotherapy (standard cytarabine and daunorubicin induction and cytarabine consolidation). Rydapt (midostaurin)is not indicated as a single-agent induction therapy for the treatment of patients with AML.

  • Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

How does Rydapt (midostaurin) work?

The active substance in Rydapt is midostaurin, a kinase inhibitor that works by blocking several enzymes that promote cell growth2,4.

Midostaurin demonstrated the ability to inhibit FLT3 receptor signalling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors. Midostaurin also demonstrated the ability to inhibit KIT signalling, cell proliferation, and histamine release and induce apoptosis in mast cells1,4.

Is Rydapt (midostaurin) approved?

Rydapt (midostaurin) was approved for patients newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy; and for patients with systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)1,3 by:

  • Food and Drug Administration (FDA) (USA) on April 28, 2017
  • European Medicines Agency (EMA) (EU) on October 25, 2017

How do I take Rydapt (midostaurin)?

The standard dosage for AML is:

  • 50 mg (2 capsules) orally twice daily with food.

The standard dosage for ASM, SM-AHN, and MCL is:

  • 100 mg (4 capsules) orally twice daily with food.
Complete information about Rydapt (midostaurin) dosage and administration can be found in the resources section. 

Note: Consult your treating doctor for personalised dosing.

Are there any known side effects of Rydapt (midostaurin)?

Among the common side effects in patients with AML are low levels of white blood cells with fever (febrile neutropenia), nausea and inflammation of the mucous membranes (mucositis)1.

Among the patients with ASM, SM-AHN, or MCL the most common adverse reactions (≥ 20%) were nausea, vomiting, diarrhea, edema, musculoskeletal and abdominal pain1.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1.

More Information
Working ingredient midostaurin
Shipping method Standard (not temperature controlled)
Package 112
Therapeutic Area Haematology
Oncology Leukemia
Indication FLT3 mutation-positive acute myeloid leukemia (AML), Systemic mastocytosis
Administration Oral
Mode of Action Kinase inhibitor (chemotherapy)
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA
Marketing Authorisation Holder Novartis Europharm Limited

The safety and efficacy of Rydapt (midostaurin) for patients with AML was based on a study involving 717 previously untreated patients. Although a specific median survival rate could not be reliably estimated it emerged that patients who received Rydapt (midostaurin) in combination with chemotherapy lived longer than patients who received chemotherapy alone. In addition, patients who received Rydapt (midostaurin) in combination with chemotherapy lived for a median of 8.2 months without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death), compared with a median of 3 months in patients who received chemotherapy alone2,3.


The safety and efficacy of Rydapt (midostaurin) for patients with advanced systemic mastocytosis (SM) was based on a main study that enrolled 116 adult patients with relapse or progression to 0, 1, or 2 prior regimens for SM, of which 89 were considered as evaluable for response1,3. Of these, 21% achieved complete (CR) or incomplete remission (ICR) within 6 cycles, and the effect lasted for an estimated median of 35.4 months (range: 6.6+, 65.8+). The median time to response was 0.5 months and ranged from 0.1 to 3.0 months1. The efficacy of midostaurin was confirmed in other patient groups as well1.

1. Summary of Product Characteristics [FDA]: Rydapt (midostaurin) [PDF]
    Novartis Pharma Co., Apr 2017. 

2. FDA approves new combination treatment for acute myeloid leukemia
    FDA, April 2017

3. Summary of Product Characteristics [EMA]: Rydapt (midostaurin) [PDF]
    Novartis Pharma Co., Oct. 2017. 

4. Human medicines: Rydapt (midostaurin)
    EMA

Shipping Type Standard
Shipping method Standard (not temperature controlled)
Dynamic Weight No
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Our Support team is available between
9:00–18:00 Central European Time, Monday to Friday.

 

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, German, Italian, Lithuanian, Mandarin, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

5.0
22 reviews

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

5.0
22 reviews

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!

Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.
learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.